Cargando…

Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma

BACKGROUND: The relationship between progression-free survival and time to progression (PFS/TTP) and overall survival (OS) has been demonstrated in a variety of solid tumours but not in metastatic renal cell carcinoma (mRCC). METHODS: A systematic literature search was conducted to identify controll...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delea, T E, Khuu, A, Heng, D YC, Haas, T, Soulières, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461161/ https://www.ncbi.nlm.nih.gov/pubmed/22935581 http://dx.doi.org/10.1038/bjc.2012.367

Ejemplares similares

Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer
por: Sherrill, B, et al.
Publicado: (2008)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
por: Amdahl, Jordan, et al.
Publicado: (2016)

Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies
por: Procopio, G, et al.
Publicado: (2012)

Review of guidelines on the treatment of metastatic renal cell carcinoma
por: Soulières, D.
Publicado: (2009)

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
por: Österlund, P, et al.
Publicado: (2011)

Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2
por: Gill, David M, et al.
Publicado: (2016)

Progression‐free survival at 2 years post‐autologous transplant: a surrogate end point for overall survival in follicular lymphoma
por: Jiménez‐Ubieto, Ana, et al.
Publicado: (2017)

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma
por: Cella, D, et al.
Publicado: (2012)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
por: Motzer, R J, et al.
Publicado: (2013)

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α
por: Patil, S, et al.
Publicado: (2012)

High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients
por: Pichler, M, et al.
Publicado: (2013)

Long-term renal and overall survival of critically ill patients with acute renal injury who received continuous renal replacement therapy
por: Wu, Lingping, et al.
Publicado: (2017)

The effect of antioxidant status on overall survival in renal cell carcinoma
por: Pavlović, Ivan, et al.
Publicado: (2019)

Determinants of Overall and Progression-Free Survival of Nigerian Patients with Philadelphia-Positive Chronic Myeloid Leukemia
por: Oyekunle, Anthony A., et al.
Publicado: (2015)

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
por: Golan, T, et al.
Publicado: (2014)

Contemporary Treatment of Metastatic Renal Cell Carcinoma
por: Stukalin, Igor, et al.
Publicado: (2016)

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer
por: Joulain, F, et al.
Publicado: (2013)

Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer
por: Bertorelle, R, et al.
Publicado: (2013)

Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients
por: Khoja, Leila, et al.
Publicado: (2016)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinoma
por: Barkan, Ella, et al.
Publicado: (2023)

An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma
por: Royston, P, et al.
Publicado: (2006)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma
por: Gilabert, M, et al.
Publicado: (2013)

Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival
por: Marinoff, Amanda E., et al.
Publicado: (2017)

Nomogram prediction for overall survival of patients diagnosed with cervical cancer
por: Polterauer, S, et al.
Publicado: (2012)

A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival
por: Parker, C, et al.
Publicado: (2006)

Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable
por: Vogl, U M, et al.
Publicado: (2006)

Predictors of Progression-Free Survival and Overall Survival in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Single-Center Experience
por: Barua, Sasanka Kumar, et al.
Publicado: (2019)

The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
por: Castro, Daniela, et al.
Publicado: (2023)

Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel
por: Langer, C J, et al.
Publicado: (2015)

Factors influencing overall survival rates for patients with pineocytoma
por: Clark, Aaron J., et al.
Publicado: (2010)

Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer
por: Burzykowski, Tomasz, et al.
Publicado: (2019)

Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors
por: Berghoff, A S, et al.
Publicado: (2012)

Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer
por: Mathew, P, et al.
Publicado: (2008)

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
por: Cella, D, et al.
Publicado: (2013)

The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma
por: Shinohara, N, et al.
Publicado: (2011)

Targeting the Endothelin Axis with Atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma
por: Groenewegen, G, et al.
Publicado: (2012)

Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma
por: Bharwani, N, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vjg8pr26b5qq2enslrqt1odvm7